生物标志物定义的常见疾病亚组：《孤儿药法案》覆盖范围的政策与经济影响
Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
作者信息
Kesselheim Aaron S, Treasure Carolyn L, Joffe Steven
机构信息
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Department of Medical Ethics & Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America.
出版信息
PLoS Med. 2017 Jan 3;14(1):e1002190. doi: 10.1371/journal.pmed.1002190. eCollection 2017 Jan.
Abstract
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
摘要
亚伦·凯塞尔海姆及其同事研究了2009年至2015年期间在美国获批的孤儿指定药物。
Zotero 插件